XML 12 R5.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Operating activities:    
Net loss $ (3,160) $ (32,768)
Adjustments to reconcile net loss to net cash used in operating activities:    
Stock-based compensation expense 3,375 7,947
Depreciation and amortization 689 718
Amortization of debt discount 88  
Amortization of debt issuance costs 52 51
Accretion of discount on short-term investments (638) (474)
Impairment of property and equipment 170 154
Changes in operating assets and liabilities:    
Accounts receivable (5,185) 601
Inventory (363) 2,514
Prepaid expenses and other assets (222) 906
Accounts payable (2,403) 840
Accrued clinical and manufacturing liabilities (2,347) (3,195)
Accrued payroll and employee liabilities (1,577) (3,906)
Other accrued and other non-current liabilities 2,005 1,712
Net cash used in operating activities (9,516) (24,900)
Investing activities:    
Purchases of short-term investments (37,892) (13,942)
Maturities and sales of short-term investments 39,170 51,000
Purchases of property and equipment   (224)
Net cash provided by investing activities 1,278 36,834
Financing activities:    
Payments for stock issued under the equity incentive plan 11 (208)
Net cash provided by (used in) financing activities 11 (208)
Net (decrease) increase in cash and cash equivalents (8,227) 11,726
Cash and cash equivalents at beginning of period 28,677 15,364
Cash and cash equivalents at end of period 20,450 $ 27,090
Supplemental disclosure of cash flow information:    
Interest paid $ 649